Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences' Essig to shift from executive to non-executive chairman July 1

Neutral Impact 3 of 5 leadership Written later

Integra LifeSciences' board approved the transition of Dr. Stuart M. Essig from Executive Chairman to non-executive Chairman, effective July 1, 2025, and the filing says the change does not result from any disagreement with the company or board. At the May 9, 2025 annual meeting, stockholders elected all eight director nominees, approved a 2,200,000-share increase to the equity incentive plan, and ratified PricewaterhouseCoopers LLP as auditor for 2025.

Key points

  • Board approved Dr. Essig's move from Executive Chairman to non-executive Chairman, effective July 1, 2025.
  • The filing states the transition is not the result of any disagreement with the company or board on operations, policies or practices.
  • Stockholders approved Amendment No. 2 to the equity incentive plan, adding 2,200,000 shares: 69,088,553 for and 2,388,890 against.
  • All eight director nominees were elected; PricewaterhouseCoopers LLP was ratified for fiscal 2025 with 72,960,045 votes for.

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECMay 13, 2025, 4:45 PM ET
Accession number0000917520-25-000052

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.